Parathyroid

C75.0WHO Vol. 10

Endocrine & Neuroendocrine System

Prognosis

This section is being prepared by our editorial process.

🔬 Histological Types

📚 Latest Research

2026-09-08

[Pathological diagnosis and molecular mechanisms of parathyroid-related hereditary syndromes].

Zhou YT, et al

This review article from the Chinese Journal of Pathology examines the pathological diagnostic criteria and underlying molecular mechanisms of hereditary parathyroid syndromes, a group of conditions that includes syndromes strongly predisposing to parathyroid neoplasia such as Multiple Endocrine Neoplasia type 1 (MEN1), hyperparathyroidism–jaw tumour syndrome (HPT-JT), and familial isolated hyperparathyroidism. By systematically mapping the genetic alterations — including mutations in MEN1, CDC73/HRPT2, and related tumour-suppressor genes — to their corresponding histopathological features, the paper provides a framework for distinguishing benign adenomas from parathyroid carcinoma in hereditary contexts. Accurate classification of these syndromes is clinically significant because it guides surveillance, surgical planning, and cascade genetic testing for at-risk family members.

Zhonghua bing li xue za zhi = Chinese journal of pathology

Source →

2026-09-03

Parathyroid carcinoma in a nonorthotopic supraclavicular location: a 20-year course.

Shibue K, et al

A case of parathyroid carcinoma was ultimately diagnosed after a nearly 20-year course of recurrent primary hyperparathyroidism (PHPT) requiring four surgical interventions, with the malignant tumor discovered in a rare nonorthotopic supraclavicular location. Longitudinal assessment revealed progressively increasing Ki-67 proliferative indices across successive resections, and the final surgery demonstrated capsular and venous invasion consistent with carcinoma. Technetium-99m methoxyisobutylisonitrile (MIBI) uptake became progressively weaker over time and eventually appeared as faint signal in the nonorthotopic site, suggesting evolving tumor biology. This case underscores the diagnostic challenges of recurrent PHPT and the critical importance of long-term follow-up, careful reassessment of atypical lesion locations, and vigilant interpretation of changing imaging and proliferative markers.

JCEM case reports

Source →

2026-09-01

Para This, Fibromin That: The Role of CDC73 in Parathyroid Tumors and Familial Tumor Syndromes.

Ababneh E, et al

Alterations in the CDC73 gene underlie three distinct categories of parathyroid tumors recognized by the World Health Organization — hyperparathyroidism-jaw tumor (HPT-JT) syndrome-associated adenomas, atypical parathyroid tumors (APTs), and parathyroid carcinomas (PCs) — collectively termed parafibromin-deficient parathyroid tumors, defined by loss of nuclear parafibromin expression detectable on routine tissue staining. Growing data indicate that parafibromin-deficient parathyroid carcinomas carry a higher rate of recurrence or metastasis compared with their parafibromin-intact counterparts, while loss of parafibromin expression also identifies APTs that fall short of a conclusive carcinoma diagnosis yet behave clinically like malignant tumors. Recognizing these characteristic morphologic features — including abundant eosinophilic cytoplasm with perinuclear clearing, hemangiopericytoma-like vasculature, thick capsule, and cystic spaces — in clinical practice can trigger germline CDC73 testing, enabling a diagnosis of HPT-JT syndrome and guiding long-term surveillance and family screening.

Clinics in laboratory medicine

Source →